MORGAN STANLEY PLC/CALL/GILEAD SCIENCES/92.5/0.1/20.12.24 Stock MORGAN STANLEY PLC/CALL/GILEAD SCIENCES/92.5/0.1/20.12.24
Add to a list
To use this feature you must be a member
Log inSign up

MORGAN STANLEY PLC/CALL/GILEAD SCIENCES/92.5/0.1/20.12.24 Stock

Warrant

DE000MB331F2

Market Closed - Bid/Ask 02:22:38 2024-07-08 pm EDT Pre-market 02:00:27 am
0.053 EUR +8.16% Intraday chart for MORGAN STANLEY PLC/CALL/GILEAD SCIENCES/92.5/0.1/20.12.24 0.058 +9.43%
Current month-19.70%
1 month+32.50%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes
Chart GILEAD SCIENCES, INC.
Chart MORGAN STANLEY PLC/CALL/GILEAD SCIENCES/92.5/0.1/20.12.24

Latest news about GILEAD SCIENCES, INC.

Raymond James Upgrades Gilead Sciences to Outperform From Market Perform, Price Target is $93 MT
HIV Breakthrough - Drug Trial Shows Injection Twice a Year Is 100 Percent Effective Against Infection [analysis] AQ
HOOKIPA Pharma Reports First Patient Dosed in HIV Treatment Study MT
HOOKIPA Pharma Inc. Announces First Person Dosed in Phase 1b Clinical Trial of HB-500 for the Treatment of HIV CI
More news

Quotes 5-day view

Date Price Change
24-07-08 0.053 +8.16%
24-07-05 0.049 +11.36%
24-07-04 0.044 -13.73%
24-07-03 0.051 -13.56%
24-07-02 0.059 -7.81%

Delayed Quote Börse Stuttgart

Last update July 08, 2024 at 02:22 pm EDT

More quotes

Static data

Product typePlain-Vanilla-Warrants
Buy / SellCALL
Underlying GILEAD SCIENCES, INC.
Issuer Morgan Stanley
WKN MB331F
ISINDE000MB331F2
Date issued 2023-02-01
Strike 92.5 $
Maturity 2024-12-20 (165 Days)
Parity 10 : 1
Emission price 0.99 €
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 1.08 €
Lowest since issue 0.024 €
Spread 0.01 €
Spread %15.87%

Company Profile

Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows: - sale of drugs (98.9%): for the treatment of HIV (63% of net sales), COVID-19 (20.4%), hepatitis C virus (6.6%), hepatitis B virus (3.6%) and other (6.4%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV); - other (1.1%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products. Net sales are distributed geographically as follows: the United States (69.2%), Europe (16.4%) and other (14.4%).
Sector
-
More about the company

Ratings for Gilead Sciences, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings

Consensus: Gilead Sciences, Inc.

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
67.55 USD
Average target price
83.34 USD
Spread / Average Target
+23.37%
Consensus
  1. Stock Market
  2. Warrants
  3. Warrant